5-hydroxymethylcytosine and its potential roles in development and cancer

Only a few years ago it was demonstrated that mammalian DNA contains oxidized forms of 5-methylcytosine (5mC). The base 5-hydroxymethylcytosine (5hmC) is the most abundant of these oxidation products and is referred to as the sixth DNA base. 5hmC is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The biological role of 5hmC is still unclear. Current models propose that 5hmC is an intermediate base in an active or passive DNA demethylation process that operates during important reprogramming phases of mammalian development. Tumors originating in various human tissues have strongly depleted levels of 5hmC. Apparently, 5hmC cannot be maintained in proliferating cells. Furthermore, mutations in the TET2 gene are commonly observed in human myeloid malignancies. Since TET proteins and many lysine demethylases require 2-oxoglutarate as a cofactor, aberrations in cofactor biochemical pathways, including mutations in isocitrate dehydrogenase (IDH), may affect levels of 5hmC and 5mC in certain types of tumors, either directly or indirectly. We discuss current data and models of the function of 5hmC in general, with special emphasis on its role in mechanisms of development and cancer.

[1]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[2]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[3]  W. Reik,et al.  Epigenetic Reprogramming in Plant and Animal Development , 2010, Science.

[4]  Che-Kun James Shen,et al.  The Mammalian de Novo DNA Methyltransferases DNMT3A and DNMT3B Are Also DNA 5-Hydroxymethylcytosine Dehydroxymethylases*♦ , 2012, The Journal of Biological Chemistry.

[5]  A. D. Hershey,et al.  NUCLEIC ACID ECONOMY IN BACTERIA INFECTED WITH BACTERIOPHAGE T2 , 1953, The Journal of general physiology.

[6]  J. Jui,et al.  Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis. , 2013, Cell reports.

[7]  Peng Jin,et al.  5-hmC–mediated epigenetic dynamics during postnatal neurodevelopment and aging , 2011, Nature Neuroscience.

[8]  Frank Lyko,et al.  Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. , 2013, Developmental cell.

[9]  Swati Kadam,et al.  Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine , 2010, Nucleic acids research.

[10]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[11]  W. Reik,et al.  5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. , 2011, Nature communications.

[12]  Y. Shinkai,et al.  PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos , 2012, Nature.

[13]  L. Aravind,et al.  Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids , 2009, Cell cycle.

[14]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[15]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[16]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[17]  K. Yen,et al.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities , 2010, Oncogene.

[18]  G. Pfeifer,et al.  H3K9me2 attracts PGC7 in the zygote to prevent Tet3-mediated oxidation of 5-methylcytosine. , 2012, Journal of molecular cell biology.

[19]  Yi Zhang,et al.  Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. , 2011, Genes & development.

[20]  Y. Hayashi,et al.  LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). , 2002, Cancer research.

[21]  Poshen B. Chen,et al.  Mbd3/NURD Complex Regulates Expression of 5-Hydroxymethylcytosine Marked Genes in Embryonic Stem Cells , 2011, Cell.

[22]  Anne H. O'Donnell,et al.  Mammalian cytosine methylation at a glance , 2009, Journal of Cell Science.

[23]  L. Sowers,et al.  An unexpectedly high excision capacity for mispaired 5-hydroxymethyluracil in human cell extracts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. D. Hershey,et al.  NUCLEIC ACID ECONOMY IN BACTERIA INFECTED WITH BACTERIOPHAGE T2 , 1953, The Journal of general physiology.

[25]  W. Reik,et al.  Active demethylation of the paternal genome in the mouse zygote , 2000, Current Biology.

[26]  H. Aburatani,et al.  Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation , 2012, Cancer science.

[27]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[28]  G. Pfeifer,et al.  Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine , 2011, Proceedings of the National Academy of Sciences.

[29]  Xiaodong Cheng,et al.  Excision of 5-hydroxymethyluracil and 5-carboxylcytosine by the thymine DNA glycosylase domain: its structural basis and implications for active DNA demethylation , 2012, Nucleic acids research.

[30]  A. Lloyd,et al.  Differential effect of three base modifications on DNA thermostability revealed by high resolution melting. , 2012, Analytical chemistry.

[31]  Xiaodong Cheng,et al.  Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation , 2012, Nucleic acids research.

[32]  A. H. Smits,et al.  Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives , 2013, Cell.

[33]  T. Carell,et al.  Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. , 2012, Angewandte Chemie.

[34]  Iris Antes,et al.  Recognition of 5-Hydroxymethylcytosine by the Uhrf1 SRA Domain , 2011, PloS one.

[35]  Yi Zhang,et al.  Replication-Dependent Loss of 5-Hydroxymethylcytosine in Mouse Preimplantation Embryos , 2011, Science.

[36]  G. Pfeifer,et al.  Genomic mapping of 5-hydroxymethylcytosine in the human brain , 2011, Nucleic acids research.

[37]  L. Sowers,et al.  Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. , 2007, Cancer research.

[38]  A. Klein-Szanto,et al.  Thymine DNA Glycosylase Is Essential for Active DNA Demethylation by Linked Deamination-Base Excision Repair , 2011, Cell.

[39]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[40]  Juri Rappsilber,et al.  TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity , 2011, Nature.

[41]  K. Bojanowski,et al.  The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. , 1972, The Biochemical journal.

[42]  Michael L. Klein,et al.  Discrimination of methylcytosine from hydroxymethylcytosine in DNA molecules. , 2011, Journal of the American Chemical Society.

[43]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[44]  J. Rowley,et al.  Leukaemogenesis: more than mutant genes , 2010, Nature Reviews Cancer.

[45]  Christian Bastard,et al.  TET2 and DNMT3A mutations in human T-cell lymphoma. , 2012, The New England journal of medicine.

[46]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[47]  T. Down,et al.  Germline DNA Demethylation Dynamics and Imprint Erasure Through 5-Hydroxymethylcytosine , 2013, Science.

[48]  N. Heintz,et al.  The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain , 2009, Science.

[49]  Chuan He,et al.  Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.

[50]  M. Surani,et al.  Parallel mechanisms of epigenetic reprogramming in the germline. , 2012, Trends in genetics : TIG.

[51]  K. Kurimoto,et al.  Replication‐coupled passive DNA demethylation for the erasure of genome imprints in mice , 2012, The EMBO journal.

[52]  Bing Ren,et al.  Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine , 2012, Nature Protocols.

[53]  M. Surani,et al.  Genome-Wide Reprogramming in the Mouse Germ Line Entails the Base Excision Repair Pathway , 2010, Science.

[54]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[55]  Colm E. Nestor,et al.  Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. , 2012, Genome research.

[56]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[57]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[58]  R. Kothari,et al.  5-methylcytosine content in the vertebrate deoxyribonucleic acids: Species specificity , 1976, Journal of Molecular Evolution.

[59]  C. Iacobuzio-Donahue,et al.  Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers , 2011, Oncotarget.

[60]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[61]  A. Bird,et al.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). , 2004, Nucleic acids research.

[62]  P. Jin,et al.  Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine , 2011, Nature Biotechnology.

[63]  M. Biel,et al.  Quantification of the sixth DNA base hydroxymethylcytosine in the brain. , 2010, Angewandte Chemie.

[64]  N. Heintz,et al.  MeCP2 binds to 5hmc enriched within active genes and accessible chromatin in the nervous system , 2012, Cell.

[65]  J. Uhm.  IDH1 and IDH2 Mutations in Gliomas , 2009 .

[66]  J. Walter,et al.  Embryogenesis: Demethylation of the zygotic paternal genome , 2000, Nature.

[67]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[68]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[70]  G. Reifenberger,et al.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics , 2012, Nature.

[71]  G. Ming,et al.  Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond , 2011, Cell cycle.

[72]  Zachary D. Smith,et al.  The simplest explanation: passive DNA demethylation in PGCs , 2013, The EMBO journal.

[73]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[74]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[75]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[76]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[77]  M. Pellegrini,et al.  Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency , 2010, Nature.

[78]  L. Aravind,et al.  Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX , 2013, Nature.

[79]  W. Reik,et al.  The Dynamics of Genome-wide DNA Methylation Reprogramming in Mouse Primordial Germ Cells , 2012, Molecular cell.

[80]  Stuart M. Brown,et al.  Definitive Identification of Mammalian 5-Hydroxymethyluracil DNAN-Glycosylase Activity as SMUG1* , 2001, The Journal of Biological Chemistry.

[81]  M. Biel,et al.  Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active Demethylation Intermediates , 2010, PloS one.

[82]  X. Shirley Liu,et al.  Tet3 CXXC Domain and Dioxygenase Activity Cooperatively Regulate Key Genes for Xenopus Eye and Neural Development , 2012, Cell.

[83]  Feng-Chun Yang,et al.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.

[84]  Z. Deng,et al.  The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes , 2011, Nature.

[85]  W. Reik,et al.  Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation , 2011, Nature.

[86]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[87]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[88]  G. Schackert,et al.  5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. , 2011, Cancer research.

[89]  J. Cigudosa,et al.  TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia , 2012, PloS one.

[90]  U. Schüller,et al.  Low values of 5‐hydroxymethylcytosine (5hmC), the “sixth base,” are associated with anaplasia in human brain tumors , 2012, International journal of cancer.

[91]  K. Rajewsky,et al.  Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice , 2011, Proceedings of the National Academy of Sciences.